On March 25, 2025, H&H Group announced its 2024 financial results, reporting a total revenue of RMB 13.05 billion (USD 1.81 billion), marking a 6.3% decline year-on-year. China remains the largest market, contributing 66.6% of total revenue. ANC (Adult Nutrition & Care) business revenue reached RMB 6.7 billion(USD 930 million), a +8.8% increase, making up 51.3% of total revenue. Swisse, the leading brand, grew +6.9% YoY in China. Swisse ranks No.1 in China’s online VHMS (Vitamins, Herbs, and Mineral Supplements) market and No.2 overall in the VHMS sector. BNC (Baby Nutrition & Care) business revenue stood at RMB 4.38 billion(USD 610 million), accounting for 33.6% of total revenue. Biostime, H&H’s core infant supplement brand, remains a market leader in China’s infant probiotic segment. Innovative product launches, including Lactoferrin + Probiotics, DHA Algal Oil + ARA Gummies, and Calcium Tablets, drove a +77.7% sales increase.
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE